L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids, L-Ornithine and L-Aspartate. It is a key hepatoprotective and detoxifying agent primarily used in the management of hepatic encephalopathy (HE) and hyperammonemia. It works by enhancing the urea cycle and glutamine synthesis in the liver and skeletal muscle, facilitating the detoxification and excretion of ammonia. In the Indian market, it is widely prescribed for acute and chronic liver diseases, including cirrhosis and alcohol-related liver damage.
Adult: Oral: 3-6 grams (commonly 1-2 sachets of 3g each) three times daily, dissolved in water/juice. Intravenous: 10-20 grams per day, infused slowly in 500 mL of IV fluid over 4-6 hours. Maximum IV dose: 40 grams/day in severe cases.
Note: Oral Granules/Sachets: Dissolve the entire content of the sachet in a glass of water or non-acidic fruit juice (approx. 150-200 mL) and consume immediately. Take after meals to improve GI tolerance. IV Infusion: Must be diluted in 500 mL of compatible IV fluid (e.g., 5% Dextrose, Normal Saline, Ringer's Lactate). Administer as a slow infusion over 4-6 hours to avoid nausea and vomiting. Do not administer as a bolus injection.
L-Ornithine L-Aspartate provides substrates for two major pathways of ammonia detoxification: 1) The Urea Cycle in periportal hepatocytes: L-Ornithine is a direct substrate, activating ornithine transcarbamylase and carbamoyl phosphate synthetase, enhancing urea synthesis. 2) The Glutamine Synthesis Pathway in perivenous hepatocytes and skeletal muscle: L-Aspartate, along with glutamate, provides substrate for glutamine synthetase, which traps ammonia as glutamine. This dual mechanism effectively lowers circulating ammonia levels.
Pregnancy: Category B: Animal reproduction studies have not shown fetal risk, but no adequate, well-controlled studies in pregnant women. Use only if clearly needed and potential benefit justifies potential risk to the fetus.
Driving: The drug itself is not known to impair driving ability. However, the underlying condition (hepatic encephalopathy) can severely impair cognitive and motor functions. Patients should not drive or operate machinery until their mental status is fully cleared and stabilized.
| Potassium-Sparing Diuretics (e.g., Spironolactone) | Increased risk of severe hyperkalemia due to additive effects. | Major |
| Potassium Supplements / Salt Substitutes | Increased risk of hyperkalemia. | Major |
| ACE Inhibitors (e.g., Ramipril) / ARBs (e.g., Telmisartan) | Increased risk of hyperkalemia. | Moderate |
| Corticosteroids | May counteract potassium-lowering effect, monitor electrolytes. | Moderate |
| Lactulose | Additive/synergistic effect in lowering ammonia. Commonly used together in hepatic encephalopathy. | Minor (Beneficial) |